Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mir-16 antagonist in the preparation of drugs for inhibiting non-alcoholic fatty liver disease

A fatty liver disease, 1.mir-16 technology, applied in the direction of drug combination, pharmaceutical formula, organic active ingredients, etc., can solve the problem that miRNA is not completely clear

Active Publication Date: 2022-04-22
HANGZHOU FIRST PEOPLES HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] As an important class of endogenous regulatory molecules, whether miRNA plays a regulatory role in NAFLD is not yet fully understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mir-16 antagonist in the preparation of drugs for inhibiting non-alcoholic fatty liver disease
  • Application of mir-16 antagonist in the preparation of drugs for inhibiting non-alcoholic fatty liver disease
  • Application of mir-16 antagonist in the preparation of drugs for inhibiting non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] 1. Experimental method

[0018] 1.1 Cell experiments

[0019] Experimental cells: normal human liver cell line L02 was purchased from Shanghai Fuxiang Biotechnology Co., Ltd. DMEM containing 10% FBS (Gibco no. 16000-044) at 37°C, 5% CO 2 conditions, and maintain 2×10 5 / mL concentration.

[0020] Cell Model Construction and Grouping

[0021] 1) L02 cells;

[0022] 2) L02 cell model group;

[0023] 3) L02 cell model group + antagomir NC;

[0024] 4) L02 cell model group + miR-16antagomir.

[0025] The normal human liver cell line L02 cells were induced by FFA to establish the NAFLD cell model. The specific scheme was as follows: the normal human liver cell line L02 cells were subcultured in DMEM medium containing 10% FBS until the cells reached 80-100% confluence. 1mMFFA palmitic acid treatment for 48h was successfully modeled. After successful modeling, the cells in groups 3 and 4 were transfected with antagomir NC and miR-16antagomir for 72 hours, respectively...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a miR-16 antagonist in the preparation of a drug for inhibiting non-alcoholic fatty liver disease. The sequence of the miR-16 is: AGCAGCAUUGUACAGGGCUAUGA. The inventors have proved through a large number of experiments that highly expressed miR-16 in cells is related to the occurrence of NAFLD, and inhibiting the level of miR-16 can significantly reduce the expression of pathologically related molecules in NAFLD model cells; miR-16 regulates the synthesis and decomposition of lipid metabolism in NAFLD cell models The expression of key enzymes in the pathway, inhibiting miRNA-16 can alleviate the pathological changes of fatty liver; and miR-16 Antagomir, as an inhibitor of microRNA-16, specifically inhibits the expression of microRNA-16, and can significantly inhibit NAFLD.

Description

technical field [0001] The invention relates to the application of miR-16 inhibitors in the preparation of drugs for inhibiting non-alcoholic fatty liver disease. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinicopathological syndrome characterized by diffuse hepatic bullous steatosis caused by excluding alcohol and other definite liver damage factors, including simple Chronic fatty liver and NASH evolved from it, IR and genetic susceptibility are closely related to its pathogenesis. With the improvement of living standards, the prevalence of NAFLD is increasing year by year, which constitutes an increasingly serious public health problem. [0003] Although simple steatosis is a benign disease with a good prognosis, a small number of NASH can progress to liver fibrosis, liver cirrhosis and even HCC. Therefore, research on the pathogenesis of NAFLD in each stage of the disease has become one of the current hotspots. NAFLD can increas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/7105A61P1/16
CPCA61K45/00A61K31/7105A61P1/16
Inventor 丁洁霞金洁吴旻俞立飞朱婧许湘飞夏彩霞李思颖岑盼盼
Owner HANGZHOU FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com